FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. - Wikidata - wikimedia - TriplyDB

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

http://www.wikidata.org/entity/Q34663697

about

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Genomic diversity of colorectal cancer: Changing landscape and emerging targets Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach Current targeted therapies in the treatment of advanced colorectal cancer: a review Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update Biomarkers of Angiogenesis in Colorectal Cancer A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer Treatment of peritoneal metastases from colorectal cancer Intrahepatic therapy for liver-dominant metastatic colorectal cancer Molecular phenotypes of colorectal cancer and potential clinical applications Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials Anti-angiogenic agents in metastatic colorectal cancer Management of colorectal cancer Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis Treatment of metastatic colorectal cancer: focus on panitumumab Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.Beyond RAS and BRAF: a target rich disease that is ripe for picking FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION Therapeutic options for peritoneal metastasis arising from colorectal cancer Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Role of targeted therapy in metastatic colorectal cancer Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence Mechanisms of resistance to anti-EGFR therapy in colorectal cancer RAS and BRAF in metastatic colorectal cancer management Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers Translating genomic profiling to gastrointestinal cancer treatment.

P2860

Q26738801-EDF450D7-0E23-47F1-B0B4-D9CA09372439 Q26739052-34B0C327-D55A-4E4C-A965-86105A6D1A82 Q26739681-7423E7C9-99A4-498C-9EB4-42B4320B97E3 Q26740067-10BE6CA8-4DEA-46F5-8F67-BCB584285F4C Q26747329-C9ED6D48-8119-4893-AC1C-69D7E70084E4 Q26748924-AF9BC85D-3196-4F21-AC3A-7E2F5D13920D Q26749012-0E016DEB-41D4-4E61-BC27-2703B8258200 Q26751344-3CE0BC3F-A08D-4C7D-BCC8-328AC2A7F7B6 Q26769958-D83E3FB1-00EE-4520-97EC-E20FDF02AE55 Q26771952-55FFEB22-9BDC-433E-9164-5080B5442CEF Q26774704-4B6CCCC3-977C-4120-8B05-69EE1134E3C9 Q26774713-B0D29403-AE2F-428D-9993-D48A1C9D633F Q26775522-E864A422-0BED-4732-ABF5-83DC08F193DD Q26775949-3FF20F9B-4FB8-42BD-B725-67D397F8B879 Q26778004-B8BC6256-F90C-4280-9A26-D441FF440433 Q26778891-2C3F7551-F414-407E-BC43-1988391C4BAB Q26782245-E71C3A47-F907-46F9-971F-F99127A7033A Q26783662-917954CB-8775-41C4-A992-707484708923 Q26784221-B1EACF88-4125-4C3B-8EAA-60A5C095E5FF Q26785725-B240A76D-576A-4536-8437-A2C65BD8ECE7 Q26797292-DB3DB08E-12DD-410E-AC52-5C97BF98DC15 Q26801911-DFBBFBDC-77A3-46D3-A21A-26FC2138C2AE Q26823550-7AEFEBCC-3315-4FE6-B3F9-64D377C7BBAD Q26862559-504E4752-2877-43D8-86F0-645FB3B44423 Q27022954-C7783C8F-8BAD-4FB7-A576-E2EDC84B6154 Q27853284-3FD63B2E-8E38-40AC-BA5E-5EBADE5D2A36 Q28066095-DF26A41B-274E-4B65-B404-3982554678EF Q28066171-9ABA13A0-5DE6-47AA-8E23-0F17561CDBA9 Q28067123-D151B85C-4385-432D-B8C4-7F4114834B52 Q28068654-08E7F10B-12B3-42E5-9023-4A79C168111F Q28068817-77B9D570-9578-411A-A7DE-EDC74453E6CF Q28071772-B9B0EDEC-4845-4BD1-AD5E-76E181F22485 Q28074073-BE00C8F0-6D2E-44A3-9895-552A3808AD01 Q28074175-16E14565-3D5D-45D9-B844-5B27C7D462BC Q28076490-730968C4-FC0C-4216-A05D-E664210EA13F Q28082816-9A8A3FA8-89AD-4FD5-91CC-E7ED34C4CF0D Q28084216-503A965C-B687-4106-96D8-375F10A7E662 Q28084888-C36036EA-B0B4-454F-9E7D-BDE88C8C3B4A Q28087333-5C30A987-7909-420B-87FF-0B738D1A4C24 Q30239109-F5672AAD-B278-4320-82CA-3AC6E934C734

P2860

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

http://www.wikidata.org/entity/Q34663697

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@ast

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@en

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@nl

type

label

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@ast

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@en

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@nl

prefLabel

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@ast

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@en

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@nl

P1433

Q34663697-213CCB9F-C98D-4708-B732-1A48D2748306

P1476

Q34663697-11318CD8-F70E-494B-AF2F-1A76EFF80607

P2093

Q34663697-0A5586C9-5E46-4E93-9F74-E614698B1C90

Q34663697-0E237DA4-3602-408A-80EB-AAD64389DE59

Q34663697-1038F4C2-0846-432B-9418-22F5295ACF23

Q34663697-1CFA4BC9-4867-416C-BBB6-CF6E559FA725

Q34663697-26EC04E5-6808-4AB3-895A-2DC587696657

Q34663697-2E8197AC-D9E7-4BD9-AEC4-22194B87C319

Q34663697-32A0D24A-33B6-4C45-A270-770D735D1D2D

Q34663697-3C0C4FF1-0E10-4B84-B9BB-169E9693C1E7

Q34663697-4745F6F0-B443-4E0A-A8A5-C14223375FC0

Q34663697-5021FFB2-1082-46E5-B362-C854C994D55E

P304

Q34663697-99D39C41-35AC-4CBC-8665-BB952BE6B187

P31

Q34663697-9F507F37-32A5-451F-9281-A2E8BF33B8FB

P356

Q34663697-59FB505F-6671-4217-BA50-CA6E86E12DC0

P433

Q34663697-7B566705-D7B4-46B5-9A0F-AD684033871E

P478

Q34663697-C52D33DF-4133-486B-A775-76F9B4A73E1F

P50

Q34663697-03F7AEF1-13C7-434D-9E84-4BB5D419E3AF

Q34663697-332A8712-B5B1-4D9F-B9C9-FA5E1A21FC85

P577

Q34663697-5FC2DC48-5BD8-4B8E-91FD-E4CCC2096356

P698

Q34663697-1D799FC3-AD39-473F-86E9-95B2C2F63618

P921

Q34663697-309DDAEA-0CF8-4E19-8E04-D2967EFD015C

Q34663697-41C7D4AA-5B4C-4B1E-824D-CA6480C35300

Q34663697-62AACAC3-6A45-42E1-A058-D8AB827F82F7

Q34663697-F481B082-B2B4-4C42-85FB-41C2A6882C71

P356

S1470-2045(14)70330-4

P1433

The Lancet Oncology

P1476

FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.

@en

P2093

Alexander Kiani

http://www.w3.org/2001/XMLSchema#string

Andreas Jung

http://www.w3.org/2001/XMLSchema#string

Andreas Rost

http://www.w3.org/2001/XMLSchema#string

Christian Lerchenmüller

http://www.w3.org/2001/XMLSchema#string

Christoph Kahl

http://www.w3.org/2001/XMLSchema#string

Dominik P Modest

http://www.w3.org/2001/XMLSchema#string

Frank Kullmann

http://www.w3.org/2001/XMLSchema#string

Gernot Seipelt

http://www.w3.org/2001/XMLSchema#string

Hartmut Link

http://www.w3.org/2001/XMLSchema#string

Heinz-Gert Höffkes

http://www.w3.org/2001/XMLSchema#string

P304

1065-1075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(14)70330-4

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Ursula Vehling-Kaiser

Ludwig Fischer von Weikersthal

P577

2014-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25088940

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase III clinical trial